Author

Jordi Minguillón

Centro de Investigaciones Energéticas, Medioambientales y TecnológicasORCID 0000-0003-2124-8294Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 1

Frequent Co-Authors

Adela EscuderoiD· 1 shared Aïda FalgàsiD· 1 shared Alba Garcia-Perez· 1 shared Alba Martínez‐Moreno· 1 shared André BarucheliD· 1 shared Andrew J. DeansiD· 1 shared Antonio Pérez-Martínez· 1 shared Apostol Apostolov· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Adela EscuderoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Fanconi Anaemia E3 Ligase complex activity is regulated by a druggable metabolite binding site in FANCX

Michael F. Sharp, Yi Sing Gee, Jennii Luu, Karla J. Cowley, Henry G. Beetham, Christopher G. Langendorf, Jonathan S. Oakhill, John W. Scott, Debora Cavero, Jordi Minguillón, Daqing Che, Jonathan B. Baell, Andrew J. Deans, Jordi Surrallés, Kaylene J. Simpson, Wayne Crismani

The paper identifies a druggable metabolite binding site in the FA E3 ligase complex that inhibits its activity and selectively kills BRCA1-deficient cells.

bioRxiv · Aug 7, 2026 · PreprintCancer Biology

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia

Néstor Tirado, Klaudyna Fidyt, María José Mansilla, Alba Garcia-Perez, Alba Martínez‐Moreno, Meritxell Vinyoles, Juan Alcaín, Marina García-Peydró, Heleia Roca-Ho, Narcís Fernández‐Fuentes, Mercedes Guerrero-Murillo, Aïda Falgàs, Talía Velasco-Hernández, Clara Bueno, Patrizio Panelli, , Pablo R. Menéndez

This paper develops and validates a dual-targeting CAR-T cell therapy for T-ALL that targets CCR9 and CD1a, showing improved efficacy and safety compared to single-targeting approaches.

Journal of Hematology & Oncology · Jul 1, 2025Peer-reviewedImmunology